Loading...
Cyfuse Biomedical K.K.
4892.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥673.00
¥20.00(3.06%)
Cyfuse Biomedical K.K. (4892.T) Financial Performance & Income Statement Overview
Review Cyfuse Biomedical K.K.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-10.91%
↓ 10.91%
Operating Income Growth
-28.49%
↓ 28.49%
Net Income Growth
-48.03%
↓ 48.03%
Operating Cash Flow Growth
-35.26%
↓ 35.26%
Operating Margin
-1344.02%
↓ 1344.02%
Gross Margin
21.90%
↑ 21.90%
Net Profit Margin
-1201.20%
↓ 1201.20%
ROE
-30.62%
↓ 30.62%
ROIC
-33.39%
↓ 33.39%
Cyfuse Biomedical K.K. (4892.T) Income Statement & Financial Overview
Review Cyfuse Biomedical K.K.'s (4892.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $28.00M | $8.00M | $7.30M | $10.74M |
| Cost of Revenue | $18.00M | $9.00M | $15.24M | $4.53M |
| Gross Profit | $10.00M | -$1.00M | -$7.95M | $6.22M |
| Gross Profit Ratio | $0.36 | -$0.13 | -$1.09 | $0.58 |
| R&D Expenses | $0.00 | $0.00 | $100.28M | $131.53M |
| SG&A Expenses | $231.00M | $225.00M | $110.79M | $236.00M |
| Operating Expenses | $232.00M | $225.00M | $220.13M | $236.17M |
| Total Costs & Expenses | $250.00M | $234.00M | $226.31M | $240.69M |
| Interest Income | $0.00 | $0.00 | $17000.00 | $13000.00 |
| Interest Expense | $0.00 | $0.00 | $2.42M | $2.08M |
| Depreciation & Amortization | $9.50M | $10.00M | $9.06M | $8.38M |
| EBITDA | -$211.50M | -$216.00M | -$209.96M | -$213.07M |
| EBITDA Ratio | -$7.55 | -$27.00 | -$28.77 | -$19.83 |
| Operating Income | -$222.00M | -$226.00M | -$219.01M | -$229.95M |
| Operating Income Ratio | -$7.93 | -$28.25 | -$30.01 | -$21.40 |
| Other Income/Expenses (Net) | $15.00M | $9.00M | -$3.29M | $6.26M |
| Income Before Tax | -$207.00M | -$217.00M | -$222.30M | -$223.69M |
| Income Before Tax Ratio | -$7.39 | -$27.13 | -$30.46 | -$20.82 |
| Income Tax Expense | $1.00M | $0.00 | $635000.00 | $585000.00 |
| Net Income | -$208.00M | -$217.00M | -$222.94M | -$224.28M |
| Net Income Ratio | -$7.43 | -$27.13 | -$30.55 | -$20.87 |
| EPS | -$25.56 | -$26.68 | -$27.77 | -$28.38 |
| Diluted EPS | -$25.56 | -$26.68 | -$27.77 | -$28.38 |
| Weighted Avg Shares Outstanding | $8.14M | $8.13M | $8.03M | $7.90M |
| Weighted Avg Shares Outstanding (Diluted) | $8.14M | $8.13M | $8.03M | $7.90M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan